Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionJohn J.V. McMurray, Anna-Maria Langkilde, Michael Böhm et al.|New England Journal of Medicine|2019Cited by 6.8k
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsSøren Lund Kristensen, John J.V. McMurray, Rasmus Rørth et al.|The Lancet Diabetes & Endocrinology|2019Cited by 1.6k
Sex differences in procedural and clinical outcomes following rotational atherectomyThomas J. Ford, Margaret McEntegart, Adnan Khan et al.|Catheterization and Cardiovascular Interventions|2019Cited by 34
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HFKieran F. Docherty, John J.V. McMurray|JACC Heart Failure|2022Cited by 13
Effect of Dapagliflozin in Patients with Diabetes and Heart Failure with Mildly Reduced or Preserved Ejection Fraction According to Background Glucose-Lowering Therapy: A Pre-Specified Analysis of the DELIVER TrialMats Christian Højbjerg Lassen, Muthiah Vaduganathan, John W. Ostrominski et al.|European Journal of Heart Failure|2024Cited by 11